Effects of dexmedetomidine on patient-controlled intravenous analgesia after pediatric scoliosis orthopedics: single center, randomized, subject and assessor blind, controlled clinical study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041028

Enrollment

Unknown

Registered

2020-12-16

Start date

2020-12-31

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric scoliosis orthopedics

Interventions

Low dose Dexmedetomidine group:Sufentanil 0.05µg/kg/h+dexmedetomidine 0.05µg/kg/h PCIA

High dose Dexmedetomidine group:Sufentanil 0.05µg/kg/h+dexmedetomidine 0.1µg/kg/h PCIA

Control group:Sufentanil 0.05µg/kg/h PCIA

Eligibility

Sex/Gender

All

Age

1 Years to 14 Years

Inclusion criteria

Inclusion criteria: Aged 18-65 years scheduled to receive scoliosis orthopedics under general anesthesia; Weight is ±15% of standard weight (standard weight (kg) = height (cm) -100); Informed consent signed.

Exclusion criteria

Exclusion criteria: Allergy to dexmedetomidine; Obvious abnormalities of heart, lung, liver, renal function and endocrine function; Patients who can not cooperate with this trial.

Design outcomes

Primary

Measure	Time frame
Postoperative opioid analgesic dosage;Effective pressing times and total pressing times of analgesia pump;pain;	—

Secondary

Measure	Time frame
Remedial analgesics dosage;satisfaction;LOS;	—

Countries

China

Contacts

Public ContactZhu Bo

PUMCH

zhubo@pumch.cn+86 10-69152020

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026